Lead time and prognostic role of serum cea, ca19-9, il-6, crp, and ykl-40 after adjuvant chemotherapy in colorectal cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
Final published version, 1.3 MB, PDF document
In colorectal cancer (CRC), 20–50% of patients relapse after curative-intent surgery with or without adjuvant therapy. We investigated the lead times and prognostic value of post-adjuvant (8 months from randomisation to adjuvant treatment) serum CEA, CA19-9, IL-6, CRP, and YKL-40. We included 147 radically resected stage II–IV CRC treated with 24 weeks of adjuvant 5-fluorouracilbased chemotherapy in the phase III LIPSYT-study (ISRCTN98405441). All 147 were included in lead time analysis, but 12 relapsing during adjuvant therapy were excluded from post-adjuvant analysis. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired disease-free survival (DFS) with hazard ratio (HR) 5.21 (95% confidence interval 2.32–11.69); 3.72 (1.99–6.95); 2.58 (1.18–5.61), respectively, and elevated IL-6 and CRP with impaired overall survival (OS) HR 3.06 (1.64–5.73); 3.41 (1.55–7.49), respectively. Elevated post-adjuvant IL-6 in CEA-normal patients identified a subgroup with impaired DFS. HR 3.12 (1.38–7.04) and OS, HR 3.20 (1.39–7.37). The lead times between the elevated biomarker and radiological relapse were 7.8 months for CEA and 10.0–53.1 months for CA19-9, IL-6, CRP, and YKL-40, and the lead time for the five combined was 27.3 months. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired DFS. The lead time was shortest for CEA.
Original language | English |
---|---|
Article number | 3892 |
Journal | Cancers |
Volume | 13 |
Issue number | 15 |
Number of pages | 16 |
ISSN | 2072-6694 |
DOIs | |
Publication status | Published - 2021 |
Bibliographical note
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
- CA19-9, CEA, Colorectal cancer, CRP, IL-6, Lead time, Post-adjuvant, Prognostic biomarker, Tumour marker, YKL-40
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 276850011